An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden.

Abstract

OBJECTIVE:

To evaluate tamsulosin (α-blocker therapy) for male overactive bladder (OAB) and to examine if indicators of concomitant benign prostatic hyperplasia are associated with OAB symptom improvement.

MATERIALS AND METHODS:

This was a planned, exploratory analysis of a 4-week, α-blocker (tamsulosin 0.4 mg) run-in phase of the Male Overactive Bladder Trial in Veterans (MOTIVE). Participants with urinary urgency and urinary frequency (> 8 voids/24 hours) completed bladder diaries, answered symptom questionnaires (AUA-7 SI), and had post-void residual and noninvasive uroflowmetry measurement.

RESULTS:

A total of 116 male Veterans aged 42-88 years with OAB participated. There were statistically significant reductions in voiding frequency (11.3 > 10.0 voids/24 hours, P < .0001), urgency scores (mean 2.5-2.2 points, P < .0001), and nightly nocturia (2.1 > 1.8, P < .001). Only baseline AUA-7 SI total and voiding subscale categories (mild, moderate, severe) were associated with significant reduction in AUA-7 SI total score. For continuous variables, only AUA-7 SI baseline total score was associated with AUA-7 SI storage symptom changes. No other baseline measures were associated with changes in urgency, frequency, or nocturia.

CONCLUSION:

Initiation of short course tamsulosin therapy in men was associated with statistical reduction in OAB symptoms. Baseline post-void residual, uroflow rate, and the voiding symptom subscore of the AUA-7 SI were not predictive of OAB symptom improvement with tamsulosin. These findings merits further exploration.

• Authors: Theodore M Johnson 2nd, Patricia S Goode, Lee Hammontree, Alayne D Markland, Camille P Vaughan, Joseph G Ouslander, Kerac Falk, Gerald McGwin Jr, Kathryn L Burgio
• Journal: Urology (Urology) Vol. 153 Pg. 42-48 (07 2021) ISSN: 1527-9995 [Electronic] United States
• PMID: 33482134 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Copyright © 2021 Elsevier Inc. All rights reserved.

Chemical References

• Adrenergic alpha-1 Receptor Antagonists
• Tamsulosin

Topics

• Adrenergic alpha-1 Receptor Antagonists (therapeutic use)
• Adult
• Aged
• Aged, 80 and over
• Cost of Illness
• Humans
• Male
• Middle Aged
• Prospective Studies
• Prostatic Hyperplasia (complications)
• Symptom Assessment
• Tamsulosin (therapeutic use)
• Treatment Outcome
• Urinary Bladder, Overactive (diagnosis, drug therapy, etiology)